TR200100030T2 - Antiviral mokrosiklik bileşikler - Google Patents
Antiviral mokrosiklik bileşiklerInfo
- Publication number
- TR200100030T2 TR200100030T2 TR2001/00030T TR200100030T TR200100030T2 TR 200100030 T2 TR200100030 T2 TR 200100030T2 TR 2001/00030 T TR2001/00030 T TR 2001/00030T TR 200100030 T TR200100030 T TR 200100030T TR 200100030 T2 TR200100030 T2 TR 200100030T2
- Authority
- TR
- Turkey
- Prior art keywords
- compounds
- microcyclic
- antiviral
- present
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Mevcut bulus yeni antiviral bilesimler,farmasötik kompozisyonlar ve onlarin kullanimlari ile ilgilidir.Daha özel olarak bu bulus HIV-ya da FIV enfekte olmus hücrelere karsi standart testlerde aktiviteye sahip olmakla beraber,ligandlarin birçok memeli embriyonik gelisme islemine aracilik eden kemokin alicilarina baglanmasi ile ilgili diger biyolojik aktiviteye sahip monosiklik poliamin türevleri ile ilgilidir.Mevcut bulus ayrica kemokin alici ligand baglanmasi tarafindan aracilik edilen çesitli hastaliklarin tedavi metodlarini da içerir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/111,895 US6506770B1 (en) | 1996-06-06 | 1998-07-08 | Antiviral compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200100030T2 true TR200100030T2 (tr) | 2001-06-21 |
Family
ID=22341015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/00030T TR200100030T2 (tr) | 1998-07-08 | 1999-07-08 | Antiviral mokrosiklik bileşikler |
Country Status (17)
Country | Link |
---|---|
US (6) | US6506770B1 (tr) |
EP (1) | EP1095031B1 (tr) |
JP (1) | JP4637353B2 (tr) |
KR (1) | KR100778134B1 (tr) |
CN (2) | CN100339080C (tr) |
AP (1) | AP1436A (tr) |
AU (1) | AU767359B2 (tr) |
BR (1) | BR9912524A (tr) |
CA (1) | CA2336634C (tr) |
HU (1) | HUP0102930A3 (tr) |
IL (1) | IL140605A0 (tr) |
MX (1) | MXPA01000137A (tr) |
NO (1) | NO20010047L (tr) |
NZ (1) | NZ509699A (tr) |
PL (1) | PL345516A1 (tr) |
TR (1) | TR200100030T2 (tr) |
WO (1) | WO2000002870A1 (tr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
US20050085555A1 (en) * | 1997-08-21 | 2005-04-21 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
WO2001044229A1 (en) * | 1999-12-17 | 2001-06-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
CA2419219A1 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
US7052676B2 (en) * | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
CN102302493B (zh) * | 2001-07-31 | 2015-08-12 | 健赞股份有限公司 | 活化祖细胞/干细胞的方法 |
US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
KR20040068339A (ko) * | 2001-12-21 | 2004-07-30 | 아노르메드 인코포레이티드 | 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물 |
US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
JP3949708B2 (ja) | 2003-04-02 | 2007-07-25 | タイゲン・バイオテクノロジー | ケモカイン受容体介在疾患を治療するためのポリアミン化合物 |
US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
NZ542850A (en) | 2003-04-22 | 2007-12-21 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
WO2005051927A1 (ja) * | 2003-11-26 | 2005-06-09 | Kureha Corporation | Hiv-1感染末梢血単核球の刺激培養によるcd4陽性t細胞の培養方法、及びhiv-1の増殖阻害剤 |
WO2006020891A2 (en) * | 2004-08-13 | 2006-02-23 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
WO2006116185A2 (en) * | 2005-04-25 | 2006-11-02 | Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
CN101365336B (zh) * | 2005-08-19 | 2013-05-29 | 健赞股份有限公司 | 增强化疗的方法 |
WO2007036036A1 (en) * | 2005-09-29 | 2007-04-05 | British Columbia Cancer Agency Branch | Method and composition for increasing the engraftment efficiency of stem cells |
EP2407171A3 (en) | 2006-02-02 | 2012-04-11 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
EP2043640A2 (en) * | 2006-06-12 | 2009-04-08 | Pfizer Products Inc. | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients |
BRPI0714799A2 (pt) * | 2006-08-02 | 2013-05-21 | Genzyme Corp | terapia de combinaÇço |
EP2056853A1 (en) * | 2006-08-07 | 2009-05-13 | Genzyme Corporation | Combination therapy |
US20090274687A1 (en) * | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
JP2012516354A (ja) * | 2009-01-30 | 2012-07-19 | ジェンザイム・コーポレーション | 乳癌を治療するための方法及び組成物 |
US8410066B2 (en) * | 2009-05-01 | 2013-04-02 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
WO2012061662A1 (en) * | 2010-11-03 | 2012-05-10 | Glycomimetics, Inc. | Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors |
KR20140045411A (ko) | 2011-05-16 | 2014-04-16 | 젠자임 코포레이션 | Cxcr4 길항제의 용도 |
CN103159690B (zh) * | 2011-12-14 | 2015-03-25 | 朱靖华 | 对称大环胺化合物的结晶形式 |
HUE036253T2 (hu) | 2011-12-22 | 2018-06-28 | Glycomimetics Inc | E-szelektin antagonista vegyületek |
HUE038423T2 (hu) | 2012-12-07 | 2018-10-29 | Glycomimetics Inc | E-szelektin antagonistákat felhasználó vegyületek, készítmények és eljárások vérképzõ sejtek mobilizációjára |
CN103058998B (zh) * | 2013-01-16 | 2016-04-13 | 山东鲁北药业有限公司 | 一种amd3465的制备工艺 |
ES2754549T3 (es) | 2014-12-03 | 2020-04-20 | Glycomimetics Inc | Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4 |
BR112017019437A2 (pt) * | 2015-04-02 | 2018-05-02 | Proximagen Ltd | terapias para câncer |
WO2017011517A1 (en) | 2015-07-16 | 2017-01-19 | Emory University | Bis-amines, compositions, and uses related to cxcr4 inhibition |
US20180296551A1 (en) * | 2015-10-19 | 2018-10-18 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating neurodegenerative diseases |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
WO2017216373A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Cxcr4 receptor-binding compounds useful for increasing interferon level |
CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CN116554168A (zh) | 2016-06-21 | 2023-08-08 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
CA3037850A1 (en) | 2016-10-07 | 2018-04-12 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
CN111683669A (zh) | 2017-10-31 | 2020-09-18 | 美真达治疗公司 | 用于造血干细胞和祖细胞移植疗法的组合物和方法 |
JP7412341B2 (ja) | 2017-10-31 | 2024-01-12 | エディジーン バイオテクノロジー インコーポレイテッド | 造血幹細胞および前駆細胞の増幅のための組成物および方法 |
WO2019108750A1 (en) | 2017-11-30 | 2019-06-06 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
CA3083783A1 (en) | 2017-12-06 | 2019-06-13 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
CN109988153B (zh) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | 一种川芎嗪衍生物及其制备方法和应用 |
CA3085356A1 (en) | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
CA3087527A1 (en) | 2018-01-03 | 2019-07-11 | Magenta Therapeutics, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
EP3761994A1 (en) | 2018-03-05 | 2021-01-13 | GlycoMimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
WO2020139962A1 (en) | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
US20220401481A1 (en) | 2019-11-01 | 2022-12-22 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
AU2021263754A1 (en) | 2020-04-27 | 2022-12-01 | Ensoma, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
AU762472B2 (en) | 1998-03-13 | 2003-06-26 | University Of British Columbia, The | Therapeutic chemokine receptor antagonists |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
EP1745797A3 (en) * | 1998-03-24 | 2007-07-18 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
WO1999065507A1 (en) | 1998-06-19 | 1999-12-23 | The General Hospital Corporation | Modulating platelet function |
AU5241099A (en) * | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
WO2005002522A2 (en) * | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
US7315917B2 (en) * | 2005-01-20 | 2008-01-01 | Sandisk Corporation | Scheduling of housekeeping operations in flash memory systems |
-
1998
- 1998-07-08 US US09/111,895 patent/US6506770B1/en not_active Expired - Lifetime
-
1999
- 1999-07-08 CN CNB2005100094866A patent/CN100339080C/zh not_active Expired - Lifetime
- 1999-07-08 PL PL99345516A patent/PL345516A1/xx not_active Application Discontinuation
- 1999-07-08 TR TR2001/00030T patent/TR200100030T2/tr unknown
- 1999-07-08 NZ NZ509699A patent/NZ509699A/en not_active IP Right Cessation
- 1999-07-08 AP APAP/P/2001/002043A patent/AP1436A/en active
- 1999-07-08 KR KR1020017000220A patent/KR100778134B1/ko not_active IP Right Cessation
- 1999-07-08 WO PCT/CA1999/000619 patent/WO2000002870A1/en active IP Right Grant
- 1999-07-08 BR BR9912524-2A patent/BR9912524A/pt not_active Application Discontinuation
- 1999-07-08 EP EP99928956.4A patent/EP1095031B1/en not_active Expired - Lifetime
- 1999-07-08 US US09/743,561 patent/US6872714B1/en not_active Expired - Lifetime
- 1999-07-08 IL IL14060599A patent/IL140605A0/xx unknown
- 1999-07-08 JP JP2000559101A patent/JP4637353B2/ja not_active Expired - Lifetime
- 1999-07-08 CA CA002336634A patent/CA2336634C/en not_active Expired - Fee Related
- 1999-07-08 HU HU0102930A patent/HUP0102930A3/hu unknown
- 1999-07-08 AU AU45959/99A patent/AU767359B2/en not_active Expired
- 1999-07-08 MX MXPA01000137A patent/MXPA01000137A/es active IP Right Grant
- 1999-07-08 CN CNB998082600A patent/CN1195745C/zh not_active Expired - Fee Related
-
2001
- 2001-01-04 NO NO20010047A patent/NO20010047L/no not_active Application Discontinuation
-
2002
- 2002-05-09 US US10/143,692 patent/US6756391B2/en not_active Expired - Lifetime
-
2004
- 2004-06-21 US US10/872,735 patent/US7160872B2/en not_active Expired - Fee Related
- 2004-11-17 US US10/991,944 patent/US7414065B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 US US12/182,044 patent/US7709486B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200100030T2 (tr) | Antiviral mokrosiklik bileşikler | |
Xiao et al. | Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1 | |
TR200000073T2 (tr) | 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi | |
DE60042030D1 (de) | Chemokinrezeptor-bindende heterocyclische verbindungen | |
TR200201225T2 (tr) | Heteosiklik ikameli pirazolonlar. | |
NL188544C (nl) | Reagens voor immunochemische analysemethoden, uitgevoerd in aanwezigheid van een waterige vloeistof. | |
DE3484832D1 (de) | Nachweis von bakterien mittels nukleinsaeuren-hybridisation, markierte sonden und testsatz dafuer. | |
ATE515575T1 (de) | Verfahren und sonden für den nachweis von krebs | |
ATE226247T1 (de) | Menschliche neuronale nikotin-acetylcholin- rezeptor-verbindungen und methoden ihres einsatzes | |
MX9203401A (es) | Anticuerpos antagonistas de la interleukina-4 humana. | |
DK1131471T3 (da) | Et system til cellebaseret screening | |
DK1150769T3 (da) | Ny metalblandingskatalysator, fremstilling deraf ved fælles udfældning og anvendelse deraf | |
ATE302278T1 (de) | Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen | |
NZ504112A (en) | Continuous format high throughput screening for testing compound for biological activity | |
TR200000113T2 (tr) | Tüberkülozu teşhis etmek için bileşikler ve bunları kullanma yöntemleri. | |
ATE148166T1 (de) | Elemente für retinsäureantwortzusammensetzung und nachweisverfahren | |
ATE109510T1 (de) | Pdgf-alpha-rezeptor. | |
DE3684741D1 (de) | Quadratfarbstoffkonjugat, dessen herstellungsverfahren und dessen verwendung bei testverfahren sowie testsaetze. | |
ATE445701T1 (de) | Zytokine rezeptor zcytor19 | |
DK0809807T3 (da) | Immunoassay til tælling af celler | |
BR9913942A (pt) | Polinucleotìdeo e polipeptìdeo isolado, vetor de expressão, célula cultivada, constructo de dna codificador de uma proteìna de fusão, processos de produção de uma proteìna, de fusão de um polipeptìdeo e de um anticorpo para o polipeptìdeo e de detecção, em uma amostra de teste, da presença de um modulador da atividade da proteìna zalpha11 e de um ligante de receptor zalpha11 dentro de uma amostra de teste, e, anticorpo | |
ATE6548T1 (de) | Vorrichtung zur durchfuehrung von mikroanalysen. | |
DE69028095T2 (de) | M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen | |
DE69427484D1 (de) | Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma | |
ATE420365T1 (de) | Präparierung von sphären für diagnostische tests |